To improve the basis for the stratification of patients with refractory and relapsed acute myeloid leukemia (AML) univariate and multivariate analyses of prognostic factors were performed in 254 patients (median age 50 years, range 18-74) undergoing S-HAM salvage chemotherapy during two consecutive prospective trials of the German AML Cooperative Group. In a multivariate analysis, duration of the first complete remission (CR) was the only factor associated with time to treatment failure (P = 0.0223). Disease-free survival was influenced by a short duration of the first CR of less than 6 months (P = 0.0001), WBC (P = 0.0018), blast count (P = 0.0037), and neutrophil count (P = 0.0119). The achievement of CR was related to the hemoglobin level only (P = 0.0457), the early death rate was related to age only (P = 0.0109), and survival was related to the bilirubin level only (P = 0.0166). In the subgroup of 104 patients in whom additional karyotype analyses were performed prior to first-line therapy unfavorable chromosome abnormalities were associated with a lower CR rate (univariate analysis, P = 0.0342; CR 24% vs 53%) and were the only factor related to survival. These analyses warrant the further evaluation of the impact of cytogenetic abnormalities on the outcome of patients with advanced AML in order to improve the characterization according to duration of first CR and to WBC of distinct subgroups of patients with differing prognoses as a basis for stratification in future trials. Leukemia (2000) 14, 226-231.
Introduction
Increasing insights into the biology of acute myeloid leukemia (AML) reveals a substantial heterogeneity within this disease and allows discrimination of distinct biologic subgroups. [1] [2] [3] They are characterized by specific chromosomal abnormalities and related to treatment outcome. 4, 5 Hence, the translocation t(15;17) is characteristic for acute promyelocytic leukemia and guides its treatment with all-trans retinoic acid. [6] [7] [8] Cases with core binding factor leukemias as defined by t (8;21) and inv (16) seem to benefit from high-dose cytosine arabinoside (AraC). 2 On the other hand, AML accompanied by complex chromosome abnormalities has a dismal prognosis and requires new therapeutic strategies. 9 While cytogenetic analyses are nowadays established as a mandatory part of initial diagnostic workup and may serve for the stratification of treatment, little information exists about its relevance for the management of refractory and relapsed disease. [10] [11] [12] Previous analyses were focussed on the duration of first remission but were frequently hampered by the heterogeneity of different salvage regimens. 11, 12 The current analysis of the prognostic significance of pretreatment factors for response to chemotherapy and long-term outcome was performed in 254 patients, from two consecutive prospective trials of the German AML Cooperative Group, who were uniformly treated by the sequential high-dose AraC and mitoxantrone (S-HAM) regimen 13 as second-line therapy.
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Patients and methods
Patients
Consecutive patients aged 18 or older with relapsed and refractory AML who were admitted at the participating centers between September 1987 and January 1996 were eligible for the two consecutive studies. The diagnosis of AML was based on the revised French-American-British (FAB) Group criteria. 15 Refractoriness against standard chemotherapy was defined according to previously established criteria: 10 These included (1) primary resistance against two cycles of induction therapy; (2) first early relapse with a remission duration of less than 6 months; and (3) second and subsequent relapse. Patients with first relapses after 6 months remission duration were not considered refractory to standard therapy and were included as relapsed AML.
All patients were recruited from the first-line trials of the German AML Cooperative Group and had thus received a standardized first-line treatment. In patients less than 60 years of age first-line therapy consisted of double induction therapy with either the repetitive application of the 9 day regimen of thioguanine, AraC, daunorubicin (TAD-9/TAD-9) or the sequential application of TAD-9 followed by high-dose AraC and mitoxantrone (HAM). Older patients all received one course of TAD-9 and were treated by a second TAD-9 or HAM course only upon inadequate response to the first TAD-9 cycle. Patients of all ages who achieved a complete remission (CR) subsequently received TAD-9 for consolidation and monthly maintenance therapy for 3 years. 16, 17 Patients who had received an allogeneic bone marrow transplantation were excluded from the study. Further exclusion criteria comprised: coronary heart disease; heart failure; cardiomyopathy; severe arterial hypertension; abnormal liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (AP) more than three times the upper normal limits; total bilirubin Ͼ2.0 mg/dl); impaired renal function (serum creatinine Ͼ2.0 mg/dl); severe infections; or pregnancy.
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Antileukemic therapy
Patients meeting the entry criteria were enrolled into the current study and were treated by S-HAM 13 comprising AraC every 12 h by a 3-h infusion on days 1, 2, 8 and 9 and mitoxantrone 10 mg/m 2 day as a 30-min infusion on days 3, 4, 10 and 11, respectively. During the first study period from September 1987 to September 1992, patients younger than 60 years were randomized to receive AraC at a dose of 3 g/m 2 or 1 g/m 2 per application while older patients were randomized between AraC at a dose of 1 g/m 2 or 0.5 g/m 2 per application. Based on the results of this comparison, 18 during the second study period from September 1992 to January 1996 patients younger than 60 years with refractory disease, early relapse following a first CR of less than 6 months, or second and subsequent relapses received AraC at doses of 3.0 g/m 2 per application while all other patients were treated with 1.0 g/m 2 AraC per single dose. Only during this second study period were patients randomly assigned to receive antifungal prophylaxis with fluconazole or not which had no effect on the outcome following S-HAM therapy. 19 These patients also received granulocyte colony-stimulating factor (G-CSF) 5 g/m 2 subcutaneously starting on day 14, ie 2 days following the completion of chemotherapy as supportive therapy. 20 G-CSF was stopped in the case of persistence of more than 5% leukemic blasts on a day 18 bone marrow examination or upon recovery of granulocytes to more than 1500/l. To avoid imbalances in the patients' risk profile the respective randomization procedures were stratified for the following criteria:
(1) primary resistance against two cycles of induction therapy; (2) first early relapse with a remission duration of less than 6 months; (3) first relapse with a remission duration of more than 6 months but less than 18 months; (4) first relapse with a remission duration of more than 18 months; (5) second and subsequent relapse.
Patients in CR after S-HAM therapy were scheduled to undergo an allogeneic transplantation when available or to receive no further therapy.
Study parameters
Bone marrow examinations were carried out on day 18, ie 1 week after the end of chemotherapy, and upon full recovery of peripheral blood counts. Response to therapy was assessed according to CALGB criteria. 21 CR was defined as a normal cellular bone marrow with normal erythroid and myeloid elements and less than 5% myeloblasts, and with peripheral blood counts of more than 100 000/l platelets and more than 1500/l granulocytes for at least 4 weeks. Patients with regenerated peripheral blood values but more than 5% and less than 25% myeloblasts were considered to be in partial remission (PR), as were patients fulfilling the bone marrow criteria of CR but without full recovery of peripheral blood platelet and/or white blood cell counts. Patients with persisting leukemic blasts in the bone marrow or blood or with leukemic regrowth within 4 weeks after initial response were considered as non-responders (NR). Patients dying within 6 weeks after the end of antileukemic therapy without evidence of leukemic regrowth were classified as early deaths (ED).
Survival and time to treatment failure (TTF) were measured
Leukemia by the time from the beginning of treatment to death, documentation of persisting leukemia, or relapse, respectively. Disease-free survival (DFS) was measured by the time from achievement of CR to relapse or death during CR. Actuarial values for time-dependent variables were calculated by the Kaplan-Meier method. 22 Determination of neutrophil and blasts counts were performed by local hematologists by slide examination. Cytogenetic evaluations were performed both at diagnosis and at relapse. Karyotype abnormalities were classified according to definitions previously established for the German AML Cooperative Group first line trials. [23] [24] [25] [26] Favorable abnormalities included t(8;21), t(15;17) and inv(16)/t(16;16) while unfavorable karyotypes were inv(3)/t(3;3), −5/5q−, t(6;9), −7/7q−, 11q23 abnormalities, 17p abnormalities, and complex chromosomal changes (у3 numeric and/or structural changes). All other karyotypes, including normal cases, were considered intermediate.
Statistics
Univariate and multivariate analyses were performed to evaluate the dependence of the variables CR, NR, ED, survival, TTF and DFS on pretreatment factors including age, duration of first CR (duration set to 0 months for patients with refractory disease), white blood cell count (WBC), blast count, neutrophil count, thrombocyte count, hemoglobin level, bilirubin level, lactate dehydrogenase (LDH) level, and date of therapy as continuous covariates and age below or higher than 60 years, disease status (refractory, first CR shorter than 6 months, first CR between 6 and 18 months, first CR more than 18 months, second or higher relapse), FAB subtype (M0 to M7), WHO performance status (0 to 3), extramedullary disease, sex, dose of AraC Univariate and multivariate analyses were performed for time-dependent variables by a proportional hazard model and for dichotomous variables by a logistic regression model using the PC-Statistik computer program (O Hoffmann, Gießen, Germany).
Study conduct
Prior to therapy all patients gave their informed consent for participation in the current evaluation after having been advised about the purpose and investigational nature of the study as well as of potential risks. The study design adhered to the declaration of Helsinki and was approved by the ethics committees of the participating institutions prior to its initiation.
Results
Patient characteristics
Two hundred and fifty-four evaluable patients were entered into the two studies from 33 centers in Germany and Austria. The patients' ages ranged from 18 to 74 years (median 50 years), the sex distribution was even (127/127). All patients had received prior chemotherapy for their disease as indicated above. In 107 patients high-dose AraC had been applied as part of the first-line chemotherapy. Overall, 32 (13%) patients had primary refractory disease and 60 (24%) had early relapses after a first CR of less than 6 months duration. In 102 (40%) and 44 (17%) cases the relapses occurred after a CR of more than 6 but less than 18 months and of more than 18 months duration, respectively; 16 (6%) patients suffered from second or subsequent relapses. AML subtypes were predominantly M1, M2, M4 and M5. WHO performance status was 0 in 23 (9%) patients, 1 in 96 (38%), 2 in 125 (49%) and 3 in 9 (4%) cases. Pretreatment WBC values ranged from 400 to 21 200/l (median, 3500/l), and extramedullary disease was present in 32 (13%) patients. Cytogenetic analyses were performed prior to first-line therapy in 104 patients. Karyotypes were classified as favorable, normal/intermediate, and unfavorable in 17, 70 and 17 patients, respectively. All 254 patients received one course of S-HAM therapy only. Median followup interval for surviving patients is 10.7 months from start of salvage therapy.
Antileukemic activity
Overall, 126 (50%) and 10 (4%) of the 254 evaluable patients achieved a CR and a PR, respectively, while 55 (22%) cases were NR. Sixty-three (25%) patients suffered from ED. Median actuarial values for disease-free survival and survival are 5.1 and 5.1 months, respectively (Figure 1 ). Median actuarial time to treatment failure is 3.0 months.
Univariate analyses
End points directly related to the response to treatment or to relapse of the disease, ie TTF, DFS, achievement of CR and NR, were dependent on factors directly related to the status of the disease prior to salvage therapy, ie blast count, WBC,
Figure 1
Survival and disease-free survival in 254 patients undergoing S-HAM salvage therapy. duration of first CR, neutrophil count, LDH, hemoglobin (Table 1 ). In contrast, the early death rate was dependent only on the patients' age. Accordingly, overall survival was influenced by age and bilirubin levels in addition to leukemiarelated factors, ie WBC, blast count, duration of first CR and LDH. Factors without an impact on any of the analyzed end points included FAB subtype, WHO performance status, sex, extramedullary manifestation of AML, thrombocyte count, date of salvage therapy, and administration of high-dose AraC during first-line therapy. The evaluation of the 104 patients with karyotype analysis prior to first-line therapy revealed a dependence of survival and achievement of CR on the diagnosis of an unfavorable karyotype. In these 104 patients, factors influencing survival were WBC (P = 0.0191), blast count (P = 0.0323), WHO performance status 3 (P = 0.0412) and unfavorable karyotype (P = 0.0583). The achievement of CR was dependent on the duration of first CR of more than 6 months and less than 18 months (P = 0.0213), unfavorable karyotype (P = 0.0342; CR 24% vs 53%) and WHO performance status 2 (P = 0.0414).
Multivariate analyses
The strongest association in the multivariate analyses was found for DFS with a duration of the first CR of less than 6 months ( Table 2) . Further covariates significantly related to DFS were WBC, blast count, neutrophil count, and duration of first CR. Survival was dependent on bilirubin only and TTF was dependent on the duration of first CR only (Figure 2 ). The only significant association for the achievement of CR following salvage therapy was found for hemoglobin while no significant association was found for NR in the multivariate analysis.
The multivariate analyses in the 104 patients with karyotype analysis prior to first-line therapy revealed an unfavorable karyotype as the only factor significantly associated with survival (P = 0.0360). No factor was found to be significantly related to the achievement of CR in the multivariate analysis in these patients.
Discussion
The current analyses of prognostic factors in patients receiving S-HAM salvage therapy for refractory and relapsed AML revealed that in addition to parameters reflecting the stage and the status of the disease, ie WBC, blast count, neutrophil count and duration of first CR, and to patient-related characteristics, ie age and bilirubin, the karyotype prior to first-line therapy significantly influences the overall outcome. Hence, the diagnosis of unfavorable chromosome abnormalities was the only factor significantly related to overall survival in the multivariate analysis. These data are in accordance with reports on the prognostic significance of karyotype abnormalities for the response to first-line therapy 3, 9, 19, [26] [27] [28] [29] and, furthermore, stress the results of a previous analysis in patients receiving second-line therapy which revealed the duration of the first CR and unfavorable chromosome abnormalities to be the most important prognostic factors. 11, 12 Until recently, the main criterion to estimate the prognosis
Figure 2
Time to treatment failure according to duration of first CR.
Leukemia of patients undergoing salvage therapy has been the duration of the first CR. 10 These data were generated from 150 patients having received standardized first-line 16 and second-line 10 therapies and thus provided the basis to analyze the patients' prognosis independently from possibly confounding therapeutic effects. Hence, cases with refractory disease and cases with early relapses, ie following a first CR of less than 6 months duration, had a significantly poorer response to therapy (CR rate 28% vs 59%) and overall outcome as compared with patients in relapse after a first CR of more than 6 months duration. Similar results were obtained in analyses performed in 243 patients at the MD Anderson Cancer Center in Houston, TX, USA, which also indicated that the duration of the first CR is the most important prognostic factor for response to salvage therapy with age and level of LDH being additional significant factors in a multivariate analysis. 12 However, the best cut-off point in this analysis was 12 months duration of the first CR with 19% vs 60% of the patients achieving a second CR. As in the current data bilirubin was the most important factor for overall survival with other patient-related factors (age, alkaline phosphatase) and leukemia-related factors (duration of first CR, percentage of blasts and promyelocytes) being significant in a multivariate analysis. However, 41 different salvage regimens were applied to the analyzed patients. As a consequence, it cannot be ruled out, that individual risk factors might have influenced the decision which therapy to apply and that the significance of other possible prognostic factors, ie cytogenetics, might have been underestimated.
Another analysis from the MD Anderson Cancer Center on 806 patients with refractory and relapsed AML confirmed the prognostic significance of the duration of the first CR and, in addition, stressed the importance of chromosome abnormalities for patients with a first CR of less than 1 year. 11 However, besides the use of various treatment regimens the lack of a multivariate analysis hampered this evaluation and no final conclusion can be drawn about the significance of cytogenetics as compared with the duration of the first CR on the basis of these data. Further evidence for the relevance of the 6 months cut-off point of duration of first CR came from a French study in which 240 patients receiving uniform salvage treatment according to the EMA protocol were evaluated for prognostic factors. 30, 31 The rates of CR following EMA therapy were 44% vs 78% for the respective groups while only refractory disease and hemoglobin level were significant in a multivariate analysis. Refractory disease and a hemorrhagic syndrome were associated with a short DFS and refractory disease, initial fever, and bone marrow blasts at 80% were predictive of short survival in multivariate analyses, respectively. No analyses, however, were performed on the relevance of cytogenetic abnormalities.
Unfortunately, further multivariate analyses of prognostic factors in this group of patients have not yet been reported, mainly due to relatively small sample sizes. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Thus, on the basis of the current analyses, the assignment of salvage regimens to patients with refractory and relapsed AML should be stratified not only with regard to the duration of the first CR but also with regard to chromosome abnormalities. Further patients should be evaluated to add to the current data and also to clarify the role of chromosome abnormalities determined directly prior to salvage therapy which are different to the initial karyotype in about 60% of cases. 43 The results of these further analyses should be the basis for further trials that analyze in a randomized fashion different treatment strategies in the respective subgroups of patients. In addition, the negative results of the current analyses should be kept in mind, eg, the lack of influence of the application of high-dose AraC during first-line treatment on the outcome following S-HAM salvage therapy. Furthermore, age was a prognostic factor for ED only, which might indicate that not age per se but a higher frequency of unfavorable leukemia-specific characteristics is the basis for the worse prognosis of elderly patients. 44 Hence, the study strategies outlined above should be evaluated in a large number of patients including cases refractory to high-dose AraC-containing regimens and elderly patients.
